RT Generic T1 SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? A1 Guisad-Hernandez, Paloma A1 Blanco-Lobo, Pilar A1 Villaoslada, Isabel A1 de-Felipe, Beatriz A1 Lucena, Jose M A1 Martin-Gutierrez, Guillermo A1 Castro, María Jose A1 Gutierrez-Valencia, Alicia A1 Sanchez-Codez, Maria Isabel A1 Gaboli, Mirella A1 Neth, Olaf A1 Olbrich, Peter K1 COVID-19 K1 Interferon-Stimulated Gene Factor 3 K1 Pyrazoles K1 COVID-19 Drug Treatment AB Recently, 94 inborn errors of immunity (IEI) patients suffering from COVID-19 have been described, overall demonstrating a mild phenotype [1] although more severe disease manifestations have been suggested for patients with alterations in the interferon (IFN) signaling pathway, including auto-antibodies against type I IFN [2]. Patients with STAT1 GOF mutations show a complex and often severe phenotype, combining an increased susceptibility of fungal, (myco-) bacterial and viral infections as well as autoimmune and autoinflammatory manifestations [3]. Characteristically, in response to type I and type II IFN stimulation, these patients show STAT1 hyperphosphorylation [3, 4]. Whether in the context of SARS-CoV-2 infection, the hyperactivation of the IFN-JAK1/2-STAT1 pathway would be protective (antiviral effect) or deleterious (hyperinflammation) is unclear. Ruxolitinib (a selective JAK1/2 inhibitor) has been successfully used in STAT1 GOF patients controlling many disease manifestations [5] and also resulted in improved pulmonary function and faster recovery from lymphopenia in previously healthy individuals suffering from severe COVID-19 PB Springer New York LLC YR 2021 FD 2021-06-09 LK http://hdl.handle.net/10668/17982 UL http://hdl.handle.net/10668/17982 LA en NO Guisado Hernández P, Blanco Lobo P, Villaoslada I, de Felipe B, Lucena JM, Martín Gutierrez G, et al. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? J Clin Immunol. 2021 Oct;41(7):1502-1506. DS RISalud RD Jul 31, 2025